ArticleThe journal of headache and pain2026
Functional characterisation of dura mater αCGRP degradation fragments at vascular, immune, and CGRP receptor targets.
Article in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCalcitonin gene related peptide (CGRP) is a central mediator in migraine and can trigger attacks in susceptible individuals. Therapies targeting CGRP or its receptor provide clinical benefit, but treatment responses vary. This suggests that local factors regulating CGRP availability and signalling within migraine relevant tissues may influence its biological effects. The extent and functional relevance of CGRP degradation at the dura mater, including possible effects on biomarker detection, remain insufficiently characterised.
methodsProteomic analyses were used to identify human αCGRP (hαCGRP) degradation fragments generated in rat meningeal preparations. Functional properties of full-length hαCGRP and selected degradation fragments were assessed at the dura mater, in isolated arteries, in mast cell degranulation assays, and at CGRP receptors in vitro. Fragment interactions with a CGRP ELISA were examined to assess potential interference with detection of full-length CGRP. Male Sprague Dawley rats were used for the ex vivo experiments.
resultshαCGRP disappeared rapidly in the meningeal environment and reduced transdural resistance in the dura mater. Seven predominant degradation fragments accounted for ~ 81.5% of the detected fragment pool. None of the fragments showed agonist activity at the CGRP receptor or altered dural resistance or mast cell degranulation. In vascular assays, the fragments were likewise inactive, with the exception of the C-terminal fragment hαCGRP
conclusionLocal degradation of hαCGRP at the dura mater primarily generates fragments without measurable vascular, immune, or receptor activating effects. The main consequence of this processing appears to be reduced hαCGRP bioavailability rather than formation of secondary bioactive signalling peptides. At the same time, fragment dependent interference in ELISA based detection indicates that local hαCGRP metabolism may affect interpretation of CGRP biomarker measurements in migraine relevant tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.